Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC5 | Q9UL62 | 9/20 | 0.56 |
| ▸ | TIPARP | Q7Z3E1 | 2/20 | 0.36 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.33 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.33 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.33 |
| ▸ | SMO | Q99835 | 3/20 | 0.33 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20818370 | 1.00 | TRPC5 (0.56) | TRPC5TIPARPSLC6A7MMP2POLB | |
| SCHEMBL20832042 | 0.84 | TRPC5 (0.51) | TRPC5SMARCA2SMARCA4PBRM1 | |
| SCHEMBL30476346 | 0.84 | TRPC5 (0.51) | TRPC5SMARCA2SMARCA4PBRM1 | |
| SCHEMBL25275764 | 0.78 | TRPC5 (0.60) | TRPC5TIPARPPOLB | |
| SCHEMBL20818546 | 0.76 | TRPC5 (0.49) | TRPC5TIPARPPOLBSMARCA2SMARCA4 | |
| SCHEMBL20817992 | 0.74 | TRPC5 (0.52) | TRPC5TIPARPPOLB | |
| SCHEMBL20818353 | 0.72 | TRPC5 (1.00) | TRPC5 | |
| SCHEMBL20817800 | 0.72 | TRPC5 (1.00) | TRPC5 | |
| SCHEMBL18152253 | 0.71 | SLC6A7 (0.49) | SLC6A7SMO | |
| SCHEMBL16822 | 0.71 | SLC6A7 (0.49) | SLC6A7SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| EP-3684364-A2 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019055966-A2 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | TRPC5 1439/4885TIPARP 3091/4885SLC6A7 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.